
ImmunoGen, Inc. - Strategy, SWOT and Corporate Finance Report
Description
ImmunoGen, Inc. - Strategy, SWOT and Corporate Finance Report
Summary
ImmunoGen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
ImmunoGen, Inc. (ImmunoGen or ‘the company’) is a developer of targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology. The ADC technology is comprised of the company's portfolio of cancer-cell killing agents that can be attached to antibodies for targeted delivery to cancer cells. The major partners of the company include Roche, Huadong, CytomX, Debiopharm, Bayer, Novartis, Oxford BioTherapeutics/Menarini, Fusion and Viridian use the company's ADC technology to develop anticancer therapies. ImmunoGen is headquartered in Waltham, Massachusetts, the US.
Scope
- Detailed information on ImmunoGen, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting ImmunoGen, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of ImmunoGen, Inc. including a breakdown and examination of key business segments
- Intelligence on ImmunoGen, Inc.'s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about ImmunoGen, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
- Gain understanding of ImmunoGen, Inc. and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess ImmunoGen, Inc. as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on ImmunoGen, Inc.'s business structure, strategy and prospects.
Table of Contents
42 Pages
- COMPANY OVERVIEW AND KEY FACTS
- TARGETS AND PARTNERS
- MERGERS & ACQUISITIONS
- Mergers and Acquisitions - Overview
- Mergers and Acquisitions - Deal reports
- PARTNERSHIP
- Partnership - Deal reports
- CAPITAL RAISING
- Capital Raising - Overview
- Capital Raising - Deal reports
- DIVESTMENTS
- Divestments - Overview
- Divestments - Deal reports
- APPENDIX
- Contact Us
- About MarketLine Financial Deals Database
- Deal Definition and Methodology
- About MarketLine
- List of Tables
- Table 1: Imperial Holdings Limited M&A volume and value trend (2019-YTD2023)
- Table 2: Imperial Holdings Limited M&A activity by geography (2019-YTD2023)
- Table 3: Imperial Holdings Limited capital raising volume and value trend (2019-YTD2023)
- Table 4: Imperial Holdings Limited capital raising by deal type (2019-YTD2023)
- Table 5: Imperial Holdings Limited divestments volume and value trend (2019-YTD2023)
- List of Figures
- Figure 1: Imperial Holdings Limited M&A volume and value trend (2019-YTD2023)
- Figure 2: Imperial Holdings Limited M&A activity by geography (2019-YTD2023)
- Figure 3: Imperial Holdings Limited capital raising volume and value trend (2019-YTD2023)
- Figure 4: Imperial Holdings Limited capital raising by deal type (2019-YTD2023)
- Figure 5: Imperial Holdings Limited divestments volume and value trend (2019-YTD2023)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.